Filing Flows › Cytosorbents (CTSO) › R&D spending
Cytosorbents (CTSO) R&D spending by quarter
Cytosorbents' R&D spending was $1.5M in Q2 2026 (second quarter 2026), +42% from Q1 2026. Over the last 4 quarters it ranged from $1.0M (Q1 2026) to $1.7M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $1.5M | +42% | +15% |
| Q1 2026 | $1.0M | -19% | -38% |
| Q2 2025 | $1.3M | -24% | — |
| Q1 2025 | $1.7M | — | — |
Q2 2026 at a glance
Cytosorbents, Q2 2026: revenue $9.6M (+0.2% year over year), operating margin -27.4%, net loss $4.4M, operating cash flow −$583K. The chart follows the revenue to costs, profit and cash.
Questions
What is Cytosorbents' R&D spending?
Cytosorbents' R&D spending was $1.5M in Q2 2026 (second quarter 2026), +42% from Q1 2026.
How has Cytosorbents' R&D spending changed?
Over the last 4 quarters it ranged from $1.0M (Q1 2026) to $1.7M (Q1 2025).